Meeting
2020 Genitourinary Cancers Symposium
Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.
Authors
Xiao X. Wei
Dana-Farber Cancer Institute, Boston, MA
Xiao X. Wei , Bradley Alexander McGregor , Richard J. Lee , Xin Gao , Kerry L. Kilbridge , Mark A. Preston , Matthew Mossanen , Matthew D. Ingham , Graeme S. Steele , Alyssa Klein , Eliezer Mendel Van Allen , Mariano Severgnini , Marios Giannakis , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03773666
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 507)
Abstract #
507
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande
Poster
2019 ASCO Annual Meeting
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
First Author: Thomas Powles
Poster
2019 ASCO Annual Meeting
A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).
First Author: Samuel Aaron Funt
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben